Compare abrdn Income Credit Strategies Fund (ACP) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Medtronic PLC — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while Medtronic PLC trades at $89.83 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 181× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays the higher dividend (18.2%). Which is the better fit depends on your goals.
| ACP | MDT | |
|---|---|---|
Market Cap | $641.16M | $116.07B |
Sector | Financials | Health |
52-Week High | $5.98 | $105.35 |
52-Week Low | $5.01 | $73.75 |
Dividend Yield | 18.2% | 3.18% |
Enterprise Value | — | $134.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACP trades at $5.14, up 1.18% today, with a bearish technical signal from moving averages. The stock shows a low P/E of 7.74 and P/B of 0.9, indicating potential undervaluation, while a high net income margin of 95.31% and consistent dividend payments highlight financial strength. Recent news confirms dividend declarations for 2026.
The outlook is mixed; attractive valuation and dividends offer opportunity, but volatile revenue, an unsustainable distribution rate flagged by analysts, and high leverage pose significant risks. Investor sentiment is cautious due to these fundamental concerns.
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
